PTX SECURES $7.0 M CAPITAL RAISING • $7.0 M institutional...

PTX SECURES $7.0 M CAPITAL RAISING
• $7.0 M institutional placement
• Rights issue on same terms to raise up to a further $3.4 M
18 May 2016, Melbourne, Australia: Prescient Therapeutics Limited (ASX: PTX), a clinical stage
oncology company, is pleased to advise the successful completion of an institutional placement to
raise $7.0 million.
The placement, largely to life-science focused Australian institutional investors, has been undertaken
which will involve the issue of approximately 77.7 million shares at 9.0 cents per share with 1
attaching option for every 2 shares subscribed (exercisable at 18 cents; expiring 30 June 2018). The
placement will be undertaken in two tranches. The first tranche of approximately 19.4 million shares
will be unconditional, with shareholders to approve the second tranche (of approximately 58.3 million)
and all attaching options.
PTX also announced that it will offer existing shareholders the opportunity to participate on the same
terms as the placement via a 1 for 3 non-renounceable rights issue, also at 9.0 cents per share with
an attaching 1 for 2 option (exercisable at 18 cents; expiring 30 June 2018), to raise up to an
additional circa $3.4 million. Eligible shareholders must be on the Company’s share register on the
record date on Thursday 26 May 2016.